Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Biostar Pharmaceuticals, Inc.Financial_Report.xls
EX-32.2 - Biostar Pharmaceuticals, Inc.ex32-2.htm
EX-31.1 - Biostar Pharmaceuticals, Inc.ex31-1.htm
EX-32.1 - Biostar Pharmaceuticals, Inc.ex32-1.htm
EX-31.2 - Biostar Pharmaceuticals, Inc.ex31-2.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
FORM 10-Q
 

 
(Mark One)
x
Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934

For the quarterly period ended: March 31, 2013
Or
 
¨
Transition Report Pursuant To Section 13 Or 15(d) of The Securities Exchange Act Of 1934
 
For the transition period from ______________ to _______________

Commission File Number: 001-34708
 
BIOSTAR PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
Maryland
 
20-8747899
(State or other jurisdiction of incorporation of origination)
 
(I.R.S. Employer Identification Number)

No. 588 Shiji Xi Avenue
Xianyang, Shaanxi Province
People’s Republic of China
 
712046
(Address of principal executive offices)
 
(Zip code)

86-29-33686638
(Registrant’s telephone number, including area code)

                                                                                                                                    
(Former name, former address and former fiscal year, if changed since last report)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x  No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x  No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer  ¨
   
Accelerated filer ¨
       
Non-accelerated filer ¨
   
Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨  No x

The Company had 11,596,113 shares issued and outstanding as of May 14, 2013.
 
 
TABLE OF CONTENTS
 
TO QUARTERLY REPORT ON FORM 10-Q
FOR QUARTER ENDED MARCH 31, 2013

   
Page
     
PART I  FINANCIAL INFORMATION
 
 
Item 1.
 
 
F-1
 
F-2
 
F-3
 
F-4
 
F-5
Item 2.
3
Item 3.
10
Item 4.
10
     
PART II OTHER INFORMATION
 
 
Item 1.
11
Item 1A.
11
Item 2.
11
Item 3.
11
Item 4.
11
Item 5.
11
Item 6.
12
  13

 
PART I - FINANCIAL INFORMATION

Item 1.    Condensed Consolidated Financial Statements (Unaudited)

BIOSTAR PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

 
March 31, 2013
 
December 31, 2012
 
 
(Unaudited)
 
(Audited)
 
             
ASSETS
 
             
Current Assets
           
Cash and cash equivalents
  $ 6,457,126     $ 1,759,078  
Accounts receivable, net of allowance for doubtful accounts of $3,665,864 (2012/12/31: $3,645,817)
    16,507,815       21,851,412  
Inventories - note 2)
    1,414,462       847,135  
Deposits and other receivables - note 3)
    7,751,359       7,740,673  
Income tax recoverable
    288,036       265,007  
Loan receivables - note 4)
    10,012,722       9,510,826  
Total Current Assets
    42,431,520       41,974,131  
                 
Non-current Assets
               
Deposits - note 3)
    8,766,198       8,718,258  
Deferred tax assets
    3,325,303       3,665,951  
Property and equipment, net - note 2)
    6,912,234       6,980,521  
Intangible assets, net - note 2)
    8,857,670       9,136,439  
                 
Total Assets
  $ 70,292,925     $ 70,475,300  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY
 
                 
Current Liabilities
               
Accounts and other payables
  $ 6,271,522     $ 5,732,329  
Short-term bank loans - note 5)
    4,781,562       4,755,413  
Due to a related party
    -       1,585,138  
Value-added tax payable
    462,139       629,672  
Total Current Liabilities
    11,515,223       12,702,552  
                 
Commitment and contingencies- note 9)
               
                 
Stockholders' Equity
               
Common stock, $0.001 par value, 100,000,000 shares authorized, 9,993,549 shares issued and outstanding as at March 31, 2013 and December 31 - note 6)
    9,993       9,993  
Additional paid-in capital
    23,272,923       23,266,776  
Statutory reserve - note 8)
    6,737,368       6,737,368  
Retained earnings
    23,790,717       23,229,743  
Accumulated other comprehensive income
    4,966,701       4,528,868  
Total Stockholders' Equity
    58,777,702       57,772,748  
                 
Total Liabilities and Stockholders' Equity
  $ 70,292,925     $ 70,475,300  

The accompanying notes are an integral part of these financial statements.
 

BIOSTAR PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME
(Unaudited)

   
Three months ended March 31,
 
   
2013
   
2012
 
             
Sales, net
  $ 12,091,909     $ 15,899,541  
Cost of sales
    5,403,019       5,063,150  
Gross profit
    6,688,890       10,836,391  
                 
Operating expenses:
               
Advertising expenses
    1,886,681       2,848,933  
Selling expenses
    2,197,346       2,907,801  
General and administrative expenses
    1,077,748       1,100,706  
Research and development expenses
    796,001       791,127  
Total operating expenses
    5,957,776       7,648,567  
                 
Income from operations
    731,114       3,187,824  
                 
Other income (expense)
               
Interest income
    455,231       95,694  
Interest expense
    (95,688 )     (15,035 )
Other
    (2,098 )     248  
      357,445       80,907  
                 
Income before income taxes
    1,088,559       3,268,731  
                 
Provision for income tax
    527,585       1,101,316  
                 
Net Income
  $ 560,974     $ 2,167,415  
                 
Foreign currency translation adjustment
    437,833       255,460  
                 
Comprehensive Income
  $ 998,807     $ 2,422,875  
                 
Net income per share
               
     Basic and diluted
  $ 0.06     $ 0.23  
                 
Weighted average number of common shares outstanding
               
     Basic and diluted
    9,993,549       9,398,892  

 The accompanying notes are an integral part of these financial statements.
 
 
BIOSTAR PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

   
Common Stock - note 6)
                           
   
Shares
   
Amount
   
Additional
Paid-in Capital
   
Statutory Reserve
    Retained Earnings    
Accumulated Other
Comprehensive Income
   
Total Stockholders' Equity
 
Balance, December 31, 2011 (Audited)
    9,400,216       9,400       22,445,660       6,490,600       43,473,834       3,982,206       76,401,700  
Stock-based compensation
    593,333       593       821,116       -       -       -       821,709  
Transfer to statutory reserve
    -       -       -       246,768       (246,768 )     -       -  
Net loss for the year
    -       -       -       -       (19,997,323 )     -       (19,997,323 )
Foreign currency translation adjustment
    -       -       -       -       -       546,662       546,662  
Balance, December 31, 2012 (Audited)
    9,993,549       9,993       23,266,776       6,737,368       23,229,743       4,528,868       57,772,748  
Stock-based compensation
    -       -       6,147       -       -       -       6,147  
Net income for the three months
    -       -       -       -       560,974       -       560,974  
Foreign currency translation adjustment
    -       -       -       -       -       437,833       437,833  
Balance, March 31, 2013 (Unaudited)
    9,993,549     $ 9,993     $ 23,272,923     $ 6,737,368     $ 23,790,717     $ 4,966,701     $ 58,777,702  

The accompanying notes are an integral part of these financial statements.
 
 
BIOSTAR PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

   
Three months ended March 31,
 
   
2013
   
2012
 
CASH FLOWS FROM OPERATING ACTIVITIES
           
Net income
  $ 560,974     $ 2,167,415  
Adjustments to reconcile net income to net cash provided by operating activities:
               
Accrued interest
    (449,075 )     -  
Deferred tax assets
    360,387       516,128  
Depreciation and amortization
    458,931       456,376  
Recognition of deferred research and development expenses
    796,001       791,127  
Stock-based compensation
    6,147       43,282  
Changes in operating assets and liabilities:
               
Accounts receivable
    5,457,403       716,639  
Inventories
    (562,015 )     428,007  
Deposits and other receivables
    (764,161 )     43  
Accounts payable and accrued expenses
    507,140       1,761,799  
Value-added tax payable
    (170,796 )     (67,397 )
Income tax payable/recoverable
    (21,547 )     (1,065,938 )
Exchange difference
    -       (901 )
Net cash provided by operating activities
    6,179,389       5,746,580  
                 
CASH FLOWS FROM INVESTING ACTIVITIES
               
Purchase of property and equipment
    (4,352 )     -  
Payment for acquisition of Shaanxi Weinan
    -       (822,173 )
Net cash (used in) investing activities
    (4,352 )     (822,173 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES
               
Repayment to a related party
    (1,592,002 )     -  
Net cash (used in) financing activities
    (1,592,002 )     -  
                 
Effective of exchange rate changes on cash and cash equivalents
    115,013       74,062  
                 
Net increase in cash and cash equivalents
    4,698,048       4,998,469  
                 
Cash and cash equivalents, beginning balance
    1,759,078       16,971,789  
Cash and cash equivalents, ending balance
  $ 6,457,126     $ 21,970,258  
                 
SUPPLEMENTAL DISCLOSURES:
               
Interest received
  $ 6,945     $ -  
Interest payments
  $ 93,132     $ -  
Income tax payments
  $ 188,745     $ 1,660,292  
 
The accompanying notes are an integral part of these financial statements.

 
BIOSTAR PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1 - ORGANIZATION

Biostar Pharmaceuticals, Inc. (“Biostar” or the “Company”) was incorporated in the State of Maryland on March 27, 2007. On June 15, 2007, Biostar formed Shaanxi Biostar Biotech Ltd. (“Shaanxi Biostar”). Shaanxi Biostar is a wholly owned subsidiary of Biostar and a limited liability company organized under the laws of the People's Republic of China (the “PRC”).

On November 1, 2007, Shaanxi Biostar entered into a series of agreements including a Management Entrustment Agreement, a Shareholders’ Voting Proxy Agreement, an Exclusive Option Agreement and a Share Pledge Agreement (collectively the “Agreements”) with Shaanxi Aoxing Pharmaceutical Co., Ltd. (“Aoxing Pharmaceutical”) and its registered owners (the “Transaction”). Aoxing Pharmaceutical is a corporation formed under the laws of the PRC. According to these Agreements, Shaanxi Biostar acquired management control of Aoxing Pharmaceutical whereby Shaanxi Biostar is entitled to all of the net profits of Aoxing Pharmaceutical as a management fee and is obligated to fund Aoxing Pharmaceutical’s operations and pay all of the debts. In exchange for entering into the Agreements, on November 1, 2007, the Company issued 19,832,311 shares of its common stock to Aoxing Pharmaceutical’s registered owners, representing approximately 90% of the Company’s common stock outstanding immediately after the Transaction. Therefore, the Transaction is accounted for as a reverse acquisition, and Aoxing Pharmaceutical is deemed to be the accounting acquirer in the reverse acquisition.

On July 9, 2010, following to the change in registered owners of Aoxing Pharmaceutical, a set of new Agreements had been entered into with all the existing registered owners of Aoxing Pharmaceutical on the same day.

The Agreements dated July 9, 2010 are merely replacement of the Agreements dated November 1, 2007 and therefore, there is no significant change in the contractual terms between the Agreements dated July 9, 2010 and November 1, 2007. The existing registered owners of Aoxing Pharmaceutical, Shaanxi Biostar and Biostar had mutually agreed that no consideration would be paid / payable upon the execution of the Agreements on July 9, 2010. The interest of Biostar in Aoxing Pharmaceutical was not and would not be affected by the replacement for the Agreements.
 
The Agreements provide that Shaanxi Biostar has controlling interest in Aoxing Pharmaceutical as defined by Accounting Standards Codification (“ASC”) 810, Consolidation, an Interpretation of Accounting Research Bulletin (“ARB”) No. 51, included in the Codification as ASC 810, Consolidation, which requires Shaanxi Biostar to consolidate the financial statements of Aoxing Pharmaceutical and ultimately consolidate with its parent company, Biostar (see Note 2 “Principles of Consolidation”).

In October 2011, Aoxing Pharmaceutical entered into and completed a Share Transfer Agreement to acquire Shaanxi Weinan Huaren Pharmaceuticals, Ltd (“Shaanxi Weinan”). from the holders of 100% of equity interests in Shaanxi Weinan.  Therefore, Shaanxi Weinan became a wholly owned subsidiary of Aoxing Pharmaceutical. Shaanxi Weinan is engaged in manufacturing of drugs and health products.

The Company, through its subsidiary and the Agreements with Aoxing Pharmaceutical, is engaged in the business of developing, manufacturing and marketing over-the-counter (“OTC”) and prescription pharmaceutical products in the PRC.

Note 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).

Principles of Consolidation

The consolidated financial statements include the accounts of the Company, its subsidiary and variable interest entity (“VIE”) for which the Company is the primary beneficiary. All inter-company accounts and transactions have been eliminated in consolidation. The Company has adopted ASC 810, Consolidation which requires a VIE to be consolidated by a company if that company has both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (1) the obligation to absorb losses of the VIE or (2) the right to receive benefits from the VIE”.
 
 
In determining Aoxing Pharmaceutical is a VIE of Shaanxi Biostar, the Company considered the following indicators, among others:

n  
Shaanxi Biostar has the full right to control and administer the financial affairs and daily operation of Aoxing Pharmaceutical and has the right to manage and control all assets of Aoxing Pharmaceutical. The registered owners of Aoxing Pharmaceutical as a group have no right to make any decision about Aoxing Pharmaceutical’s activities without the consent of Shaanxi Biostar.

n  
Shaanxi Biostar is assigned all voting rights of Aoxing Pharmaceutical and has the right to appoint all directors and senior management personnel of Aoxing Pharmaceutical. The registered owners of Aoxing Pharmaceutical possess no substantive voting rights.

n  
Shaanxi Biostar is committed to provide financial support if Aoxing Pharmaceutical requires additional funds to maintain its operations and to repay its debts.

n  
Shaanxi Biostar is entitled to a management fee equal to Aoxing Pharmaceutical’s net profits and is obligated to assume all operation risks and bear all losses of Aoxing Pharmaceutical.  Therefore, Shaanxi Biostar is the primary beneficiary of Aoxing Pharmaceutical.

Additional capital provided to Aoxing Pharmaceutical by the Company was recorded as an interest-free loan to Aoxing Pharmaceutical. There was no written note to this loan, the loan was not interest bearing, and was eliminated during consolidation. Under the terms of the Agreements, the registered owners of Aoxing Pharmaceutical are required to transfer their ownership of Aoxing Pharmaceutical to the Company’s subsidiary in the PRC when permitted by the PRC laws and regulations or to designees of the Company at any time when the Company considers it is necessary to acquire Aoxing Pharmaceutical. In addition, the registered owners of Aoxing Pharmaceutical have pledged their shares in Aoxing Pharmaceutical as collateral to secure these Agreements.

Unaudited Interim Financial Information

These unaudited interim consolidated financial statements have been prepared in accordance with GAAP for interim financial reporting and the rules and regulations of the Securities and Exchange Commission that permit reduced disclosure for interim periods. Therefore, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. In the opinion of management, all adjustments of a normal recurring nature necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented have been made. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for the year ending December 31, 2013.

The consolidated balance sheets and certain comparative information as of December 31, 2012 are derived from the audited consolidated financial statements and related notes for the year ended December 31, 2012 (“2012 Annual Financial Statements”), included in the Company’s 2012 Annual Report on Form 10-K. These unaudited interim consolidated financial statements should be read in conjunction with the 2012 Annual Financial Statements.

Use of Estimates

The preparation of these condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Estimates are used for, but not limited to, the accounting for certain items such as allowance for doubtful accounts, depreciation and amortization, impairment, inventory allowance, taxes and contingencies.
 
Inventories

Inventories are valued at the lower of weighted average cost or market. Management compares the cost of inventories with the market value, and allowance is made for writing down the inventories to market value, if lower. Inventories consisted of the following:

   
March 31,
   
December 31,
 
   
2013
   
2012
 
             
Raw materials
 
$
425,203
   
$
405,900
 
Work in process
   
219,440
     
125,007
 
Finished goods
   
513,331
     
193,145
 
Goods in transit
   
256,488
     
123,083
 
   
$
1,414,462
   
$
847,135
 
 
 
Property and Equipment

Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with estimated lives of:
 
Buildings
30 years
Building improvements
30 years
Machinery & equipment
5-10 years
Furniture & fixtures and vehicles
5-10 years
 
Property and equipment consisted of the following:
            
   
March 31,
   
December 31,
 
   
2013
   
2012
 
             
Buildings
 
$
3,559,116
   
$
3,539,652
 
Building improvements
   
1,980,672
     
1,969,840
 
Machinery & equipment
   
1,178,193
     
1,167,414
 
Furniture & fixtures
   
67,108
     
66,741
 
Vehicle
   
130,918
     
130,202
 
Construction in progress
   
2,095,423
     
2,083,964
 
     
9,011,430
     
8,957,813
 
Less: Accumulated depreciation
   
(2,099,196
)
   
(1,977,292
)
   
$
6,912,234
   
$
6,980,521
 

As of March 31, 2013 and December 31, 2012, all buildings of Aoxing Pharmaceutical and Shaanxi Weinan have been pledged to a financial institution in the PRC to secure short term bank loans (note 5).

Intangible Assets

Intangible assets are amortized using the straight-line method over their estimated period of benefit, ranging from ten to fifty years. Management evaluates the recoverability of intangible assets periodically and takes into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. No impairment of intangible assets have been identified for the three months ended March 31, 2013 and 2012. The Company’s land use rights will expire between 2053 and 2056. The Company’s proprietary technologies, including drug approvals and permits, were mainly contributed by four ex-owners of Aoxing Pharmaceutical and acquired from Shaanxi Weinan acquisition in last year. All of the Company’s intangible assets are subject to amortization with estimated useful lives of:
  
Land use rights
50 years
Proprietary technologies
10 years

The components of finite-lived intangible assets are as follows:
 
   
March 31,
   
December 31,
 
   
2013
   
2012
 
             
Land use rights
 
$
3,448,863
   
$
3,430,002
 
Proprietary technologies
   
8,962,142
     
8,913,131
 
     
12,411,005
     
12,343,133
 
Less: Accumulated amortization
   
(3,553,335
)
   
(3,206,694
)
   
$
8,857,670
   
$
9,136,439
 
 
 
The estimated future amortization expenses related to intangible assets as of March 31, 2013 are as follows:

 
Years Ending December 31,
     
2013 (9 months)
 
$
1,039,923
 
2014
   
1,386,564
 
2015
   
1,386,564
 
2016
   
1,386,564
 
2017
   
173,214
 
Thereafter
   
3,484,841
 
 
As of March 31, 2013 and December 31, 2012, all land use rights of Aoxing Pharmaceutical and Shaanxi Weinan are pledged to a financial institution in the PRC to secure short term bank loans (note 5).

Recent accounting pronouncements

In February 2013, the FASB issued ASU No. 2013-02, which amends the authoritative accounting guidance under ASC Topic 220 “Comprehensive Income.”  The amendments do not change the current requirements for reporting net income or other comprehensive income in financial statements.  However, the amendments require an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component.  In addition, an entity is required to present, either on the face of the statement where net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under generally accepted accounting principles in the United States of America (“GAAP”) to be reclassified to net income in its entirety in the same reporting period.  For other amounts that are not required under GAAP to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures required under GAAP that provide additional detail about those amounts.  The amendments in this update are effective prospectively for reporting periods beginning after December 15, 2013.  Early adoption is permitted.  Adoption of this update is not expected to have a material effect on the Company’s consolidated results of operations or financial condition.

As of March 31, 2013, there are no recently issued accounting standards not yet adopted that would have a material effect on the Company’s financial statements.

Note 3 – DEPOSITS AND OTHER RECEIVABLES

Deposits and other receivables consisted of the following:
 
   
March 31,
   
December 31,
 
   
2013
   
2012
 
             
Current portion
           
Deposits paid for research and development of new medicine - note 9b)
 
$
2,390,781
   
$
3,170,275
 
Deposits paid for advertising
   
1,243,206
     
475,542
 
Other receivables*
   
4,117,372
     
4,094,856
 
       Prepaid expenses and other receivables
 
$
7,751,359
   
$
7,740,673
 
                 
Non-current portion
               
Deposits paid to former equity holders of Shaanxi Weinan to acquire drug approval numbers - note 11)
 
$
8,766,198
   
$
8,718,258
 
   
$
8,766,198
   
$
8,718,258
 
 
* Other receivables are mainly from the two land use rights disposed in year 2011.

Note 4 – LOAN RECEIVABLES

On November 20, 2012, the Company advanced RMB 60 million ($9.5 million) to a third party as a commercial loan, interest bearing at 13% per annum. The principal and interest are to be repaid on December 31, 2013. As at March 31, 2013 and December 31, 2012, carrying amount of the loan receivables approximate its fair value due to short maturity.

 
Note 5 – SHORT-TERM BANK LOANS

Short-term bank loans consists of the followings:

       
Balance as at
 
Inception date
 
Details
 
March 31, 2013
   
December 31, 2012
 
                 
October 24, 2012
 
RMB 10,000,000, one year term loan, annual interest rate at7.80%
  $ 1,593,854     $ 1,585,137  
November 8, 2012
 
RMB 10,000,000, one year term loan, annual interest rate at7.80%
    1,593,854       1,585,138  
December 5, 2012
 
RMB 10,000,000, one year term loan, annual interest rate at7.80%
    1,593,854       1,585,138  
   
Total
  $ 4,781,562     $ 4,755,413  

These loans are secured by (i) personal guarantee executed by a major shareholder of the Company and (ii) pledge of all buildings and land use rights of Aoxing Pharmaceutical and Shaanxi Weinan.

As of March 31, 2013 and December 31, 2012, the carrying amount of the short-term bank loans approximates the fair values due to short maturity.
 
Note 6 – STOCKHOLDERS’ EQUITY

Reverse stock split

On April 3, 2012, the Company filed Articles of Amendment to the Company’s Articles of Incorporation with the Secretary of State of the State of Maryland to effect a one-for-three reverse stock split of the issued and outstanding common stock of the Company (the “Reverse Split”).  Par value remained unchanged at $0.001 after the reverse split.  The Reverse Split became effective on April 3, 2012.  The Reverse Split was duly approved by the Board of Directors of the Company without shareholder approval, in accordance with the authority conferred by Section 2-309(e)(2) of the Maryland General Corporation Law.

In accordance with SEC Staff Accounting Bulletin Topic 4C “Equity Accounts:  Changes in Capital Structure”, the changes in the capital structure arising from the Reverse Split must be given retroactive effect in the balance sheet, and an appropriately cross-referenced note should disclose the retroactive treatment, explain the change made and state the date the change became effective.  Unless otherwise stated, the number and price of common stocks, including warrants and options and other related disclosures made throughout these consolidated financial statements retroactively reflected the effect of such Reverse Split.

(a) Common stock

As of March 31, 2013 and December 31, 2012, the Company has 100,000,000 shares of common stock authorized, 9,993,549 shares issued and outstanding at par value of $0.001 per share.  The Company did not issue any shares of common stock during the three months ended March 31, 2012.

(b) Warrants

As at March 31, 2013 and December 31, 2012, the Company has 195,784 warrants outstanding, with weighted average exercise price of $8.67.

 
The following table summarizes the Company’s outstanding warrants as of March 31, 2013 and December 31, 2012.

         
Outstanding as at,
 
Expiry date
 
Exercise Price
   
March 31, 2013
   
December 31, 2012
 
May 31, 2013
    6.00       18,333       18,333  
June 30, 2014
    8.22       10,784       10,784  
November 1, 2014*
    9.00       166,667       166,667  
              195,784       195,784  

* The Company has the right at any time, on at least forty-five (45) day written notice, to redeem the outstanding warrants at a price of one cent ($0.03) per share provided the market price of the Company’s common stock equals to or exceeds $13.5 on each trading day for twenty (20) consecutive trading days ending on the trading day prior to the date that the Company intends to redeem the warrants. 

(c) Stock Options

In April 2012, the Company issued 24,000 stock options under the 2011 Stock Plan to one of its officers at the exercise price of $1.68 per share. The options vest in one year and expire in five years.

The following tables summarize activities for the Company’s options for the three months ended March 31, 2013 and the year ended December 31, 2012.
 
         
Weighted Average
 
   
Number of options
   
Exercise Price ($)
   
Remaining Life (years)
 
Balance, December 31, 2011
    362,222       8.22       2.94  
Granted, April 20, 2012
    24,000       1.68       4.27  
Balance, December 31, 2012
    386,222       7.81       2.08  
Balance, March 31, 2013
    386,222       7.81       1.83  
                         
Vested as at December 31, 2012
    357,777       7.40       1.59  
Vested as at March 31, 2013
    357,777       7.40       1.37  
                         
Unvested as at December 31, 2012
    28,445       2.64       3.80  
Unvested as at March 31, 2013
    28,445       2.64       3.55  

The Company recognized $6,147 and $43,282 as stock-based compensation expense, which was included in general and administrative expense, during the three months ended March 31, 2013 and 2012.  Stock-based compensations has been fully recognized as at March 31, 2013.
 
Note 7 - INCOME TAXES

The Company was incorporated in the United States of America (“USA”) and has operations in one tax jurisdiction, i.e. the PRC. The Company generated substantially all of its net income from its operations in the PRC for the three months ended March 31, 2013 and 2012, and has recorded income tax provision for the periods.

Uncertain Tax Positions

Interest associated with unrecognized tax benefits are classified as income tax, and penalties are classified in selling, general and administrative expenses in the statements of operations.

For the three months ended March 31, 2013 and 2012, the Company had no unrecognized tax benefits and related interest and penalties expenses.  Currently, the Company is not subject to examination by major tax jurisdictions.

 
Note 8 - STATUTORY RESERVES

The Company’s subsidiaries and VIE in the PRC are required to make appropriations to certain non-distributable reserve funds. In accordance with the laws and regulations applicable to China’s foreign investment enterprises and with China’s Company Laws, an enterprise’s income, after the payment of the PRC income taxes, must be allocated to the statutory surplus reserves. The proportion of allocation for reserves is 10 percent of the profit after tax to the surplus reserve fund, and the cumulative amount shall not to exceed 50 percent of registered capital.

Use of the statutory reserve fund is restricted to set offs against losses, expansion of production and operation or increase in the registered capital of a company. Use of the statutory public welfare fund is restricted to the capital expenditures for the collective welfare of employees. These reserves are not transferable to the Company in the form of cash dividends, loans or advances. These reserves are therefore not available for distribution except in liquidation. As of March 31, 2013 and December 31, 2012, the Company’s VIE had allocated $6,737,368 to these non-distributable reserve funds.
 
Note 9 - COMMITMENTS

a)  
Research and Development on clinical trials

The Company has previously entered into three agreements with certain research institutes to conduct clinical trials for two new and one existing drug.  The Company’s total commitment for these agreements is approximately $2.1 million.  As at March 31, 2013 and December 31, 2012, the Company’s total accumulated progress payment towards these clinical trials were approximately $1.3 million.  Upon completion of these clinical trials, the company will be obligated to pay approximately an additional $0.8 million.

b)  
Capital commitments

In December 2010, the Company entered into an agreement with a research institution to jointly develop a new drug for treatment of cardiovascular disease.  The development is to be carried out by the research institute.  Pursuant to the agreement, the Company’s total commitment is $11.5 million, in exchange for 60% share of the intellectual property upon successful development of the drug.  In the event that the research institute fail to successfully develop the drug, the Company’s contribution is fully refundable.  As at March 31, 2013 and December 31, 2012, the Company’s total accumulated contribution was approximately $8.8 million.  The Company is obligated to contribute approximately an additional $2.7 million in January 2014.

Note 10 - SEGMENT INFORMATION

For the three months ended March 31, 2013 and 2012, all revenues of the Company represented the net sales of pharmaceutical products. No financial information by business segment is presented. Furthermore, as all revenues are derived from the PRC, no geographic information by geographical segment is presented. All tangible and intangible assets are located in the PRC.

Note 11 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events for potential recognition and disclosure through the date of financial statements was issued.

On March 11, 2013, Aoxing Pharmaceutical entered into an agreement with all the former equity holders (“Former Equity Holders”) of Shaanxi Weinan, to acquire 13 drug approval numbers for total consideration of RMB 55 million (approximately $8.7 million) and 1,602,564 shares of the Company’s common stock. Full amount of RMB 55 million (approximately $8.7 million) has been paid up to December 31, 2012 as deposits (note 3).  The transaction has been completed in April 2013.

 
Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations.
 
The following discussion should be read in conjunction with our financial statements and the notes thereto which appear elsewhere in this report. The results shown herein are not necessarily indicative of the results to be expected in any future periods. This discussion contains forward-looking statements based on current expectations, which involve uncertainties. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "predict," "potential," "continue," "ongoing," "expect," "believe," "intend," "may," "will," "should," "could," or the negative of these terms or other comparable terminology. All forward-looking statements included in this document are based on information available to the management on the date hereof.   Actual results and the timing of events could differ materially from the forward-looking statements as a result of a number of factors. Readers should also carefully review factors set forth in other reports or documents that we file from time to time with the Securities and Exchange Commission.

You should read the following discussion and analysis in conjunction with our unaudited financial statements contained in this report as well as the audited financial statements, and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in our Annual Report on Form 10-K, as amended to date, for the fiscal year ended December 31, 2012.  We undertake no obligation and do not intend to update, revise or otherwise publicly release any revisions to our forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of any unanticipated events.

Overview

Biostar Pharmaceuticals, Inc. (“we”, the “Company” or “Biostar”) was incorporated on March 27, 2007 in the State of Maryland. Our business operation is conducted in China primarily through our variable interest entity (“VIE”), Shaanxi Aoxing Pharmaceutical Co., Ltd. (“Aoxing Pharmaceutical”), which we control through contractual arrangements between Aoxing Pharmaceutical and our wholly owned subsidiary, Shaanxi Biostar Biotech Ltd. (“Shaanxi Biostar”).

On March 28, 2010, we, through Shaanxi Biostar, entered into an agreement to acquire the assets of Xi’an Meipude Bio-Technology Co., Ltd., a Xi’an-based medical equipment manufacturer (“Meipude”), for RMB7.85 million ($1.2 million), including certain assets registered to a family member of an original Meipude shareholder. We took control over the assets of Meipude on March 29, 2010. To facilitate the transfer of some of the assets, however, we were required to acquire all of the outstanding equity interests of Meipude, which we subsequently applied for deregistration on January 18, 2011.

In October 2011, Aoxing Pharmaceutical entered into a Share Transfer Agreement to acquire Shaanxi Weinan Huaren Pharmaceuticals, Ltd. (“Shaanxi Weinan”) from the holders of 100% of equity interests in Shaanxi Weinan. The aggregate purchase price is RMB 61 million (approximately $9.55 million) in cash and payable in several tranches.

Shaanxi Weinan owns drug approvals and permits for a portfolio of 86 drugs and one health product, all of which, were added to the Company’s current drug portfolio following the completion of this acquisition. The Company completed this acquisition on October 25, 2011, and the name of the acquired company changed to Shaanxi Weinan Aoxing Pharmaceuticals, LLC.  We are in the process of integrating the administration, operation and sales functions of Shaanxi Weinan with those of Aoxing Pharmaceutical.

We currently manufacture and sell 20 over-the-counter (“OTC”) medicines, prescription-based pharmaceuticals, and health products, which are sold and distributed in over 25 provinces and provincial-level cities throughout China. We also have exclusive supply contract with a hospital to supply three pharmaceutical products.  Our best-selling product, Xin Aoxing Oleanolic Acid Capsule (“Xin Aoxing Capsule”), is a state-approved OTC drug for treatment of Hepatitis B.
 
Recent Developments

On March 11, 2013, Aoxing Pharmaceutical entered into a supplemental agreement to the Share Transfer Agreement with all the former equity holders of Shaanxi Weinan to acquire 13 drug approval numbers which were excluded from the Share Transfer Agreement due to incomplete reregistration.  Following the execution of the supplemental agreement, the Company will acquire the ownership of the 13 drug approval numbers for which reregistration has been completed. The aggregate purchase price is RMB 66 million (approximately $10.6 million) for the 13 drug approval numbers, of which RMB 30 million (approximately $4.8 million) was paid on November 26, 2012, RMB 25 million (approximately $4.0 million) was paid on December 31, 2012 and the balance of RMB 11 million (approximately $1.8 million) were paid in the Company’s common stock. Based on an agreed issuance price of $1.10 per share, RMB 11 million is equivalent to 1,602,564 shares of common stock of the Company. The Company completed this acquisition in April 2013.
 
 
Gel Capsule Related Developments (the “Capsule Incident”)
 
In April 2012, PRC State Food and Drug Administration (SFDA) launched an investigation of several capsule manufacturers based in Zhejiang, Hebei and Jiangxi provinces into their use of industrial gelatin, which contained impermissibly high chromium content. On May 25, 2012, following a nationwide inspection, SFDA authorities reported that 669 batches of gel capsules from 254 drug manufacturers in 28 provinces were found to have high chromium levels. The results of this inspection were publicly distributed in China, including publication on SFDA’s website http://www.sda.gov.cn/WS01/CL0001. As a result, SFDA effectively suspended sales of gel capsules nationwide until the investigation was completed.
 
In May 2012, following an onsite inspection by the Xianyang State Food and Drug Administration (SFDA), samples from a batch of our Xin Aoxing capsules were found to contain chromium content higher than edible gelatin. Specifically, samples from a batch of 150 cases of the Xin Aoxing capsules (each of the 150 cases contains 8,000 capsules), representing Biostar sales of approximately RMB1,188,000 or approximately $188,000 were also found to contain high levels of chromium, which capsules, in the Company’s estimation, were sold in the market in mid-2011. The Company did not check the batch in question for the chromium levels at that time since PRC pharmaceutical companies were not required to test their gel capsule inventories and purchases for chromium levels in 2011.

As required by SFDA in April 2012, the Company purchased gel capsule inspection equipment to measure the chromium levels in gel capsules it used. The Company also undertook a thorough inspection of all samples of drugs sold and its current product inventory to ensure that all of the gel capsules it had purchased and currently uses comply with the SFDA chromium content requirements.  In addition, the Company conducted checks of every batch of raw materials it uses in every production category and, except as discussed above, found no violations of the chromium content requirements. Further, the Company recalled all such affected capsules as promptly and thoroughly as possible, and imposed heightened quality control and assurance measures going forward.
 
On July 30, 2012, the SFDA approved the Company’s resumption of sales of its gel capsules following a thorough inspection of raw materials used in every production category, all samples of drugs sold and the current product inventory. However, the suspension of sales of gel capsule products severely affected all China-based pharmaceutical companies that use gelatin capsules to manufacture their drugs.  Negative publicity associated with the Capsule Incident continues to affect consumer’s confidence of capsule products.

Results of Operations

Net Sales

For the three months ended March 31, 2013, total net sales decreased by approximately $3.8 million or 23.9% compared to the same period in 2012.  The decrease is mainly attributed to the decrease in sales volume of Aoxing Pharmaceutical’s capsule products, offset by the sales of several newly introduced products. The following table illustrates our sales results for the three months ended March 31, 2013 and 2012.
 
   
Three Months Ended March 31,
   
Increase (Decrease) due to changes in
 
   
2013
   
2012
   
Product offering
   
Sales volume
   
Sales price
 
Aoxing Pharmaceutical Products
                             
Xin Aoxing Oleanolic Acid Capsule
  $ 5,443,928     $ 10,388,009     $ -     $ (5,438,584 )   $ 494,503  
Other Aoxing Pharmaceutical products
    2,502,174       3,315,975       -       (667,068 )     (146,733 )
New product
    110,155       -       110,155       -       -  
Temporarily discontinued (4 products)
    -       622,840       (622,840 )     -       -  
Sub-total
    8,056,257       14,326,824       (512,685 )     (6,105,652 )     347,770  
                                         
Shaanxi Weinan Products
                                       
Shaanxi Weinan products
    1,639,478       1,563,653               177,100       (101,275 )
New products (5 products)
    443,736       -       443,736       -       -  
Sub-total
    2,083,214       1,563,653       443,736       177,100       (101,275 )
                                         
Hospital products
    1,952,438       -       1,952,438       -       -  
                                         
Medical device
    -       9,064       (9,064 )     -       -  
                                         
Total sales
  $ 12,091,909     $ 15,899,541     $ 1,874,425     $ (5,928,552 )   $ 246,495  
 
 
Sales of our products under the Aoxing Pharmaceutical brand decreased by approximately $6.3 million, or 43.8%, for the three months ended March 31, 2013, compared to the same period in 2012.  The decrease is mainly attributable to the decrease in sales volume of our flagship product, Xin Aoxing Capsule, as well as other Aoxing Pharmaceutical products as a result of the Capsule Incident discussed above.  Decrease in sales of other Aoxing Pharmaceutical products was also attributable to increased competition from similar products.  During the three months ended March 31, 2013, we have introduced one product and temporarily discontinued four products. The products were temporarily discontinued due to expiration of their drug approval numbers, and, reregistration of the approval numbers were still pending as at March 31, 2013.

Sales of Shaanxi Weinan’s products increased by approximately $0.5 million or 33.2% for the three months ended March 31, 2013 compared to the same period in 2012.  The increase is attributable to an increase in sales volume and introduction of five new products since the second quarter in 2012.

We have also begun selling three new products exclusively to a local hospital since the third quarter in 2012.  These products accounted for approximately $2.0 million of our total net sales for the three months ended March 31, 2013.
 
Cost of sales

Compared to the same period in 2012, cost of sales decreased by about $0.3 million or 6.7% for the three months ended March 31, 2013.  This decrease is mainly due to the decrease in net sales and the temporarily discontinuation of several products, offset by cost of sales for the new hospital products.  The following table summarizes our cost of goods sold for the three months ended March 31, 2013 and 2012:

   
Three Months Ended March 31,
   
Increase (Decrease) due to changes in
   
2013
   
2012
   
Product offering
   
Sales volume
   
Product cost
Aoxing Pharmaceutical Products
                           
Xin Aoxing Oleanolic Acid Capsule
  $ 1,367,670     $ 2,135,507     $ -     $ (1,366,327 )   $ 598,490  
Other Aoxing Pharmaceutical products
    1,666,223       1,895,158       -       (407,200 )     178,265  
New Product
    79,659       -       79,659       -       -  
Temporarily discontinued (4 products)
    -       302,490       (302,490 )     -       -  
 Sub-total
    3,113,552       4,333,155       (222,831 )     (1,773,527 )     776,755  
                                         
Shaanxi Weinan Products
                                       
Shaanxi Weinan products
    703,896       723,568       -       76,770       (96,442 )
New Products (5 products)
    191,827       -       191,827       -       -  
 Sub-total
    895,723       723,568       191,827       76,770       (96,442 )
                                         
Hospital products
    1,393,744       -       1,393,744       -       -  
                                         
Medical device
    -       6,427       (6,427 )     -       -  
                                         
 Total cost of sales
  $ 5,403,019     $ 5,063,150     $ 1,356,313     $ (1,696,757 )   $ 680,313  

There was an average increase of 10.1% in the unit cost of our products, for the three months ended March 31, 2013 as compared to the same period in 2012.  The increase is attributable to increase in the cost of raw material and labor.

For the three months ended March 31, 2013, average unit cost of Xin Aoxing Capsule increased by 28.0%, compared to the same period in 2012, as we included additional products as promotional items, in addition to the increased cost of raw material and labor. Average unit cost of other Aoxing Pharmaceutical products increased by 8.3% as a result of increase in cost of raw material and labor.

Average unit cost of Shaanxi Weinan products decreased by 14.5% for the three months ended March 31, 2013, as compared to the same period in 2012.  The decrease was due to more effective control of material purchase and production management.

Cost margin of our hospital products was 71.4% for the three months ended March 31, 2013.  Management believes that we may lower the average cost of these products as we increase our sales and utilize economy of scale.
 
 
Gross Profit

Gross profit decreased by approximately $4.1 million or 38.3% for the three months ended March 31, 2013, as compared to the same period in 2012. The decrease in gross profit was due primarily to the decrease in sales volume and increase in unit cost of our products.
 
    Three Months Ended March 31,  
   
2013
   
2012
 
   
 Gross Profit
   
 Product Gross Margin %
    Gross Profit     Product Gross Margin%  
Aoxing Pharmaceutical Products
                       
 Xin Aoxing Oleanolic Acid Capsule
  $ 4,076,258       74.9 %   $ 8,252,502       79.4 %
 Other Aoxing Pharmaceutical products
    835,951       33.4 %     1,420,817       42.8 %
 New Product
    30,496       27.7 %     -       -  
 Temporarily discontinued (4 products)
    -       -       320,350       51.4 %
 Sub-total
    4,942,705       61.4 %     9,993,669       69.8 %
                                 
Shaanxi Weinan Products
                               
 Shaanxi Weinan products
    935,582       57.1 %     840,085       53.7 %
 New Product (5 products)
    251,909       56.8 %     -       -  
 Sub-total
    1,187,491       57.0 %     840,085       53.7 %
                                 
 Hospital products
    558,694       28.6 %     -       -  
                                 
 Medical device
    -       -       2,637       29.1 %
                                 
 Total gross profit
  $ 6,688,890       55.3 %   $ 10,836,391       68.2 %
 
The overall gross profit margin decreased to 55.3% for the three months ended March 31, 2013 from 68.2% for the same period in 2012 mainly because of the increase in the cost of labor and raw material for the three months ended March 31, 2013.  The decrease is also due to significant change in the sales of our product mix.  Xin Aoxing Capsule, our highest gross profit margin product, contributed 61% to total gross profit for the three months ended March 31, 2013, as compared to 76% during the same period in 2012.

Operating Expenses
 
    Three Months Ended March 31,          
    2013     2012          
    Operating expenses     % of net sales     Operating expenses     % of net sales     % change  
Advertising expenses
  $ 1,886,681       15.6 %   $ 2,848,933       17.9 %     (33.8 %)
Selling expenses
    2,197,346       18.2 %     2,907,801       18.3 %     (24.4 %)
General and administrative expenses
    1,071,601       8.9 %     1,057,424       6.7 %     1.3 %
Research and development expenses
    796,001       6.6 %     791,127       5.0 %     0.6 %
Total operating expenses
  $ 5,951,629       49.2 %   $ 7,605,285       47.8 %     (21.7 %)
 
Total operating expense decreased by approximately $1.7 million or 21.7% for the three months ended March 31, 2013, as compared to the same period in 2012.  The decrease is attributable to decrease in advertising and selling expenses.
 
 
Advertising expenses accounted for 15.6% and 17.9% of our total sales for the three months ended March 31, 2013 and 2012.  The decrease of approximately $1 million or 33.8% is due to decrease in advertising activities as a result of the temporary discontinuation of several of our products.

Selling expenses consist mostly of sales salaries, commission and other selling expenses.  Overall decrease was approximately $0.7 million or 24.4%.  The decrease is consistent with the decrease in our sales during the three months ended March 31, 2013 as compared to the same period in 2012.

General and administrative expenses consist of fixed cost such as salaries and wages, amortization and depreciation, stock based compensation and other general and administrative expenses.  For the three months ended March 31, 2013 and 2012, general and administrative expenses were approximately $1.1 million.

We make periodical assessments as to the progress of our research and development projects, and charge to expense as appropriate, as these projects reach different stages or project milestones.  We incurred a total of approximately $0.8 million in research and development expenses for the three months ended March 31, 2013 and 2012, respectively.  Our current research developments are in connection with three ongoing clinical trials for two new products and one existing products, and a joint development of a new drug with a research institution.
 
Provision for Income Taxes
 
For the three months ended March 31, 2013 and 2012, our income tax expense was approximately $0.5 and $1.1 million.  The effective tax rates, taking into consideration differences in allowable deductions, and changes in valuation allowances, were 51.5% and 30.6%, for the three months ended March 31, 2013 and 2012, respectively. The uniform corporate income tax rate is 25% in China. The calculation of effective tax rate include the operating results of all our subsidiaries, including the U.S. corporate company.

Liquidity and Capital Resources

As of March 31, 2013, we had cash and cash equivalents of approximately $6.5 million and net working capital of approximately $30.9 million.  We expect to generate sufficient cash and cash equivalents from the realization of our accounts receivables of $16.5 million and maturity of the loan receivables of $10 million.  We believe our existing cash and cash equivalents and net working capital as at March 31, 2013, as well as net cash inflows during the next two quarters will be sufficient to maintain our operations at present level for at least the next twelve months.

As at March 31, 2013, cash and cash equivalents were mainly denominated in RMB and were placed with banks in the PRC.  These cash and cash equivalents may not be freely convertible into foreign currencies and the remittance of these funds out of the PRC may be subjected to exchange control restrictions imposed by the PRC government.

On an on-going basis, we take steps to identify and plan our needs for liquidity and capital resources, to fund our operations and day to day business operations. Our future capital expenditures will include, among others, expanding product lines, research and development capabilities, and making acquisitions as deemed appropriate.
 
Based on our current plans for the next 12 months, we anticipate that the sales of the Company’s pharmaceutical products will be the primary organic source of funds for future operating activities in 2013. However, to fund continued expansion of our operation and extend our reach to broader markets, and to acquire additional entities, as we may deem appropriate, we may rely on bank borrowing, if available, as well as capital raises. There is no assurance that we will find such funding on acceptable terms, if at all.  Currently, substantially all of our buildings, building improvements and land use rights are pledged against short-term bank loans with various due dates from October to December 2013, which may restrict our abilities to obtain further bank financing until these short-term loans are repaid.

Net cash provided by operating activities for the three months ended March 31, 2013 was approximately $6.2 million. This was primarily due to our net income of approximately $0.6 million, adjusted by a non-cash decrease in deferred tax assets of approximately $0.4 million, and non-cash related expenses including depreciation and amortization of approximately $0.5 million, and research and development expenses of approximately $0.8 million, offset by non-cash accrued interest income of $0.4 million and a net increase in working capital items of approximately $4.4 million. The net increase in working capital items was mainly due to decrease in accounts receivable and increase in accounts payable and accrued expenses, offset by increase in inventories, prepaid expenses and decrease in value added taxes payable.

Net cash used in financing activities for the three months ended March 31, 2013 was approximately $1.6 million, consisting repayment of an advance from a related party.  
 
 
Critical Accounting Policies

We believe the following critical accounting policies, among others, affect management’s more significant judgments and estimates used in the preparation of the financial statements:
 
Allowance for Doubtful Accounts

We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. The allowance for doubtful accounts is based on specific identification of customer accounts and management’s best estimate of the likelihood of potential loss, taking into account such factors as the financial condition and payment history of major customers. Management evaluates the collectability of the receivables at least quarterly. If the financial condition of a customer was to deteriorate further, resulting in an impairment of their ability to make payments, additional allowances may be required.  Such differences could be material and could significantly impact cash flows from operating activities.

The following are steps the Company takes in collecting accounts receivable:

Step 1: After the payment term has been exceeded, the Company stops taking orders from the delinquent customer and allows the responsible sales person three to six months to collect the accounts receivable. Most of the accounts receivable will be collected in this step because the sales person’s compensation is tied to sales receipts. The Company’s normal sales term is 90 days credit period.

Step 2: If the sales person’s collection efforts are not successful, the Company hires a collection agent and allows the agent another three to six months to collect the accounts receivable.

Step 3: If the collection agent’s efforts are not successful, the Company will commence legal action to collect the accounts receivable.
 
Our policies for writing off the accounts receivable are as follows:

 
1.
If after taking legal action, it appears that an accounts receivable is not likely to become collectible, such accounts receivable will be written off if it is more than two years old.

 
2.
If during the collection period, the customer provides bankruptcy or other insolvency documentation, the corresponding accounts receivable will be written off.

 
3.
If we are no longer able to locate a particular customer in order for us to take any collection or legal actions, the accounts receivable for such customer will be written off if it is more than two years old.

 
Inventory

We write down our inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand, future pricing and market conditions. If actual future demands, future pricing or market conditions are less favorable than those projected by management, additional inventory write-downs may be required and the differences could be material. Such differences might significantly impact cash flows from operating activities.
 
Property and Equipment
 
Property and equipment are stated at historical cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Judgment is required to determine the estimated useful lives of assets, especially for computer equipment, including determining how long existing equipment can function and when new technologies will be introduced at cost-effective price points to replace existing equipment. Changes in these estimates and assumptions could materially impact the financial position and results of operations.

Stock-Based Compensation

Our stock-based compensation expense is estimated at the grant date based on the award’s fair value as calculated by the Black-Scholes-Merton (BSM) option-pricing model and is recognized as expense over the requisite service period. The BSM model requires various highly judgmental assumptions including expected volatility and option life. Changes in these assumptions could materially impact the financial position and results of operations.
 
Valuation of Intangibles

From time to time, we acquire intangible assets that are beneficial to our product development processes. Management periodically evaluates the carrying value of intangibles, including the related amortization periods. In evaluating acquired intangible assets, management determines whether there has been impairment by comparing the anticipated undiscounted cash flows from the operation and eventual disposition of the product line with its carrying value. If the undiscounted cash flows are less than the carrying value, the amount of the impairment, if any, will be determined by comparing the carrying value of each intangible asset with its fair value.  Fair value is generally based on either a discounted cash flows analysis or market analysis. Future operating income is based on various assumptions, including regulatory approvals, patents being granted, and the type and nature of competing products. If regulatory approvals or patents are not obtained or are substantially delayed, or other competing technologies are developed and obtain general market acceptance or market conditions otherwise change, our intangibles may have a substantially reduced value, which could be material.
 
Research and Development

The remuneration of the Company’s research and development staff, materials used in internal research and development activities, and payments made to third parties in connection with collaborative research and development arrangements, are all expensed as incurred.  Where the Company makes a payment to a third party to acquire the right to use a product formula which has received regulatory approval, that payment is accounted for as the acquisition of a license or patent and is capitalized as an intangible asset and amortized over the shorter of the remaining license period or patent life (See above “Intangible Assets”).

Income Taxes

We use the asset and liability method of accounting for income taxes. Under this method, income tax expense is recognized for the amount of taxes payable or refundable for the current year. In addition, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities and for operating losses and tax credit carry-forwards. Management must make assumptions, judgments and estimates to determine the current provision for income taxes and the deferred tax assets and liabilities and any valuation allowance to be recorded against a deferred tax asset. Management’s judgments, assumptions and estimates relative to the current provision for income tax take into account current tax laws, management’s interpretation of current tax laws and possible outcomes of current and future audits conducted by foreign and domestic tax authorities. Changes in tax law or management’s interpretation of tax laws and the resolution of current and future tax audits could significantly impact the amounts provided for income taxes in the financial statements. Management’s assumptions, judgments and estimates relative to the value of a deferred tax asset take into account predictions of the amount and category of future taxable income, such as income from operations. Actual operating results and the underlying amount and category of income in future years could render management’s current assumptions, judgments and estimates of recoverable net deferred taxes inaccurate. Any of the assumptions, judgments and estimates mentioned above could cause our actual income tax obligations to differ from the estimates, thus materially impact the financial position and results of operations.
 
 
Foreign Currency

Our functional currency is the U.S. dollar, and our subsidiary and our VIE in China use their respective local currencies as their functional currencies, i.e. the RMB. An entity’s functional currency is the currency of the primary economic environment in which the entity operates. Management must use judgment in determining an entity’s functional currency, assessing economic factors including cash flow, sales price, sales market, expense, financing and inter-company transactions and arrangements. The impact from exchange rate changes related to transactions denominated in currencies other than the functional currency is recorded as a gain and loss in the statements of operations, while the impact from exchange rate changes related to translating a foreign entity’s financial statements from the functional currency to its reporting currency, the U.S. dollar, is disclosed and accumulated in a separate component under the equity section of the balance sheets. Different judgments or assumptions resulting in a change of functional currency may materially impact our financial position and results of operations.
  
Contractual Obligations

The following table sets forth our contractual obligations as of March 31, 2013:
 
 
Payments due by period ($ million)
 
 
Total
 
Within 1 year
 
1-3 years
 
3-5 years
 
>5 years
 
Short-term bank loan
  $ 4.8     $ 4.8     $ -       -       -  
Research and development contracts
    3.5       0.8       2.7       -       -  
Total contractual obligations
  $ 8.3     $ 5.6     $ 2.7       -       -  
 
Inflation

Management believes that inflation has not had a material effect on our results of operations.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements, as defined in Regulation S-K Section 303(a)(4).

 
Item 3.    Quantitative and Qualitative Disclosures About Market Risk

We are a “smaller reporting company” as defined by Regulations S-K and as such, are not required to provide this information.

Item 4.    Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q (the “Evaluation Date”), under the supervision and with the participation of our management, including the Chief Executive Officer and Interim Chief Financial Officer (the “Certifying Officers”), have evaluated the effectiveness of our disclosure controls and procedures. Based on that evaluation, our Certifying Officers have concluded that, as of the Evaluation Date, our disclosure controls and procedures were effective such that the material information required to be filed with our SEC reports is recorded, processed, summarized, and reported within the required time periods specified in the SEC rules and forms.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the most recently completed fiscal quarter that have materially affected, or are likely to materially affect, our internal control over financial reporting.
 
 
PART II - OTHER INFORMATION

Item 1.    Legal Proceedings.

At present, the Company is not engaged in or the subject of any material pending legal proceedings.

Item 1A. Risk Factors.

We are a “smaller reporting company” as defined by Regulations S-K and as such, are not required to provide this information.

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds.

As disclosed in the Company’s current report on Form 8-K filed with the SEC on March 15, 2013, the Company issued an aggregate of 1,602,564 shares of common stock to the former equity holders of Shaanxi Weinan Huaren Pharmaceuticals., Ltd. in connection with the acquisition of 13 drug approval numbers. The sale and issuance of the Company common stock were exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”) pursuant to Regulation S promulgated thereunder. The former equity holders represented their intention to acquire the Company’s common stock for investment only and not with a view to, or for sale in connection with, any distribution thereof and appropriate legends will be affixed to the stock certificates. The former equity holders further represented they are not U.S. persons and that they will only resell the Company’s common stock in accordance with the provisions of Regulation S. Neither the Company nor anyone acting on the Company’s behalf offered or sold the Company’s common stock by any form of general solicitation or general advertising.
 
Item 3.    Defaults upon Senior Securities.
 
None.

Item 4.   Mine safety Disclosures.

Not Applicable.

Item 5.    Other Information.

None.
 
 
Item 6.    Exhibits.
 
Exhibit Number
Description
3.1
Articles of Incorporation filed with the corporate secretary of State of the State of Maryland on March 27, 2007 (1)
3.2
Articles of Amendment filed with the corporate secretary of State of the State of Maryland on August 1, 2007 (1)
3.3
Articles of Amendment filed with the corporate secretary of State of the State of Maryland on September 14, 2007 (1)
3.4
Certificate of Designation for the Series B Convertible Preferred Stock as filed with the corporate secretary of State of Maryland on November 2, 2009 (2)
3.5
Articles of Amendment to the Articles of Incorporation of Biostar Pharmaceuticals, Inc. (3)
3.6
Bylaws (1)
4.1
2009 Incentive Stock Plan ** (4)
4.2
2011 Stock Option Compensation Plan (5)**
4.3
2012 Stock Option Compensation Plan (6) **
31.1
31.2
32.1
32.2
101.INS
XBRL Instance Document
101.SCH
XBRL Taxonomy Extension Schema
101.CAL
XBRL Taxonomy Calculation Linkbase
101.LAB
XBRL Taxonomy Extension Label Linkbase
101.PRE
XBRL Taxonomy Extension Presentation Linkbase
101.DEF
XBRL Taxonomy Extension Definition Document
  
* Filed herewith.
** Management agreement or compensatory plan or agreement.

(1)
Previously filed as an exhibit to the Company’s Registration Statement on Form SB-2 (File No. 333-147363) filed with the SEC on November 13, 2007.
(2)
Previously filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on November 3, 2009.
(3)
Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on April 4, 2012.
(4)
Incorporated by reference from the Company’s Schedule 14A filed with the SEC on October 1, 2010.
(5)
Incorporated by reference from the Company’s Registration Statement on Form S-8 filed with the SEC on August 17, 2012.
(6)
Incorporated by reference from the Company’s Proxy Statement on Schedule 14A filed with the SEC on September 21, 2012.
 

 
SIGNATURES

In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
  
 
BIOSTAR PHARMACEUTICALS, INC.
 
     
Date: May 15, 2013
By:
/s/ Ronghua Wang
 
 
Ronghua Wang
Chief Executive Officer and President
(Principal Executive Officer)
 

 
Date: May 15, 2013
By:
/s/ Qinghua Liu
 
 
Qinghua Liu
Interim Chief Financial Officer
(Principal Financial and Accounting Officer)